Rosiglitazone found in anti-diabetic drug banned in India

Pune, India

09 Oct, 2010

Doctors have asked diabetes patients to stop using medicine that contains rosiglitazone. The government has now officially banned this anti-diabetic drug, though the controversy about its side effects had erupted two years ago. The anti-diabetic drug was banned by the European Medicines Agency last month for its adverse reactions. The US FDA had restricted its use. The Drug Controller General of India has now banned the use of the drug in India. The drug that is sold as Rosicon, Reglit, Windia, Windamet, Enselin, Rezult and even combination form of Rosicon G in India was sparingly used. The use of anti-diabetic drugs containing rosiglitazone formulation had dwindled since the last two years due to reports of its caedio-vascular-related side effects.

Source: Pharmabuzz Team